Connect with us

Trends

Immuno-Oncology Therapy Market to Report Impressive Growth by 2022

With the presence of a large pool of participants, the global immuno-oncology therapy market is displaying a highly competitive business landscape. Amgen Inc., Novartis AG, Pfizer, Incorporation, AstraZeneca Plc., Bristol-Myers Squibb Company, Eli-Lilly and Company, F.Hoffmann-La Roche Ltd, and GlaxoSmithKline Plc are some of the key vendors of immuno-oncology therapy across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development states the immuno-oncology therapy market study. Citing an instance, on September 24, 2018, Transgene—a France based biotech firm developing virus-based immunotherapy against cancers and contagious ailments—introduced myvacTM, a personalized viral vector-based immunotherapy against cancer projected to enter clinical development during 2019.

The global immuno-oncology therapy market stood at USD 42.97 billion in 2016. Witnessing a tremendous rise during the period from 2017 to 2022, the revenue in this immuno-oncology therapy market is expected to reach USD 97.34 billion by the end of the forecast period. Rise in cancer cases, technological innovation in cancer treatments, and rise in cancer research activities are anticipated to largely impact the growth of immuno-oncology therapy market in the near future. Apart from this, a shift from conventional chemotherapy to immunotherapy along with the need for treating many forms of cancers such as lung cancer, skin cancer, and breast cancer are predicted to boost immuno-oncology therapy market trends. In addition, the launching of new drug classes such as monoclonal antibodies and HDAC inhibitors are expected to create profit-making opportunities for immuno-oncology therapy market in the coming years.

Shortage of experienced healthcare experts, high treatment costs, and lack of awareness about the immuno-oncology therapy among the patient population base, however, can hinder the progress of immuno-oncology therapy market over the coming years. Nevertheless, growing investments in healthcare activities along with large-scale registration with health insurance firms covering cancer treatment is expected to propel immuno-oncology therapy market revenue in the years ahead. Regionally, North America has been leading the worldwide immuno-oncology therapy market and is anticipated to continue on the dominant position in the years to come, states the immuno-oncology therapy market study. Growing occurrence of cancer and the easy availability of modern therapeutics in the region is the main factor behind the dominance of the North America immuno-oncology therapy market. The high number of market players being headquartered in North America is another significant factor that is supporting this regional immuno-oncology therapy market. – Zion Market Research

Copyright © 2024 Medical Buyer

error: Content is protected !!